Nothing Special   »   [go: up one dir, main page]

CL2015001392A1 - Compuestos y sus métodos de empleo - Google Patents

Compuestos y sus métodos de empleo

Info

Publication number
CL2015001392A1
CL2015001392A1 CL2015001392A CL2015001392A CL2015001392A1 CL 2015001392 A1 CL2015001392 A1 CL 2015001392A1 CL 2015001392 A CL2015001392 A CL 2015001392A CL 2015001392 A CL2015001392 A CL 2015001392A CL 2015001392 A1 CL2015001392 A1 CL 2015001392A1
Authority
CL
Chile
Prior art keywords
compounds
methods
heterocicles
glutaminase
modulators
Prior art date
Application number
CL2015001392A
Other languages
English (en)
Inventor
Rene M Lemieux
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Jeremy M Travins
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CL2015001392A1 publication Critical patent/CL2015001392A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DERIVADOS DE HETEROCICLOS NITROGENADOS, MODULADORES DE GLUTAMINASA ; COMPOSICION FARMACEUTICA; Y UN METODO PARA TRATAR EL CANCER,
CL2015001392A 2012-11-22 2015-05-22 Compuestos y sus métodos de empleo CL2015001392A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
CL2015001392A1 true CL2015001392A1 (es) 2016-04-22

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001392A CL2015001392A1 (es) 2012-11-22 2015-05-22 Compuestos y sus métodos de empleo

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP3456719A1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN108727307A (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA201890754A1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HK (1) HK1214593A1 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150A1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG11201504049VA (es)
SI (1) SI2922850T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TW201906825A (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
RS62447B1 (sr) 2012-11-16 2021-11-30 Calithera Biosciences Inc Heterociklični inhibitori glutaminaze
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
BR112015012536A2 (pt) * 2012-12-03 2017-07-11 Calithera Biosciences Inc tratamento de câncer com inibidores heterocíclicos da glutaminase
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
SG10201912524QA (en) 2013-01-15 2020-04-29 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションIncyte Corporation Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
JP6783663B2 (ja) * 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법
AP2016009530A0 (en) 2014-04-30 2016-10-31 Pfizer Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2788449T3 (es) 2014-07-03 2020-10-21 Univ Texas Inhibidores de GLS1 para tratar enfermedades
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
WO2016022969A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
EP3280415A4 (en) 2015-04-06 2018-12-26 Calithera Biosciences Inc. Treatment of lung cancer with inhibitors of glutaminase
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
JP6895396B2 (ja) * 2015-06-30 2021-06-30 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 疾患を処置するためのgls1阻害薬
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
KR20180059544A (ko) 2015-10-05 2018-06-04 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와 면역-종양학적 약제에 의한 병용 요법
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
WO2017112831A1 (en) 2015-12-22 2017-06-29 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
EP3503886A4 (en) * 2016-08-25 2020-07-22 Calithera Biosciences, Inc. POLYTHERAPY INCLUDING GLUTAMINASE INHIBITORS
US10195197B2 (en) 2016-08-25 2019-02-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EP3697764A4 (en) 2017-10-18 2021-07-21 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3876928B1 (en) 2018-11-08 2024-10-23 Merck Sharp & Dohme LLC Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2020191356A1 (en) * 2019-03-21 2020-09-24 Goncalves Marcus Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
ES2152310T3 (es) 1993-03-29 2001-02-01 Basf Ag Derivados de 1-amino-3-fenoxipropano como moduladores de la resistencia a multiples a farmacos.
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
ATE288904T1 (de) 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
KR20100087330A (ko) 2007-11-19 2010-08-04 제넨테크, 인크. 종양 진행을 억제하기 위한 조성물 및 방법
EP2271941B1 (en) 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
US20120142028A1 (en) 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
ES2812457T3 (es) 2010-06-23 2021-03-17 Univ Louisville Res Found Inc Uso de ácidos grasos en procedimientos para detectar cáncer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
EP2844270A4 (en) 2012-03-15 2016-01-27 Univ New York State Res Found POLYTHERAPIES INCLUDING EXTRACELLULAR DOMAIN INHIBITORS OF E-CADHERHINE
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
JP6783663B2 (ja) 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법

Also Published As

Publication number Publication date
RS57859B1 (sr) 2018-12-31
US20190084976A1 (en) 2019-03-21
AU2013347771B2 (en) 2018-02-01
IL238958B (en) 2019-09-26
CN104936954B (zh) 2018-08-14
MX367389B (es) 2019-08-19
ES2690390T3 (es) 2018-11-20
EA201890754A1 (ru) 2018-08-31
HRP20181628T1 (hr) 2018-12-14
BR112015011830A2 (pt) 2017-07-11
SG11201504049VA (en) 2015-07-30
TW201906825A (zh) 2019-02-16
NZ708382A (en) 2020-04-24
PH12015501150B1 (en) 2015-08-17
IL238958A0 (en) 2015-07-30
CY1120581T1 (el) 2019-07-10
DK2922850T3 (en) 2018-10-08
HUE040111T2 (hu) 2019-02-28
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
AU2018202954A1 (en) 2018-05-17
UA117360C2 (uk) 2018-07-25
AR093598A1 (es) 2015-06-10
PH12017502141A1 (en) 2019-02-27
CA2893510A1 (en) 2014-05-30
PT2922850T (pt) 2018-10-15
US20150291576A1 (en) 2015-10-15
TR201812360T4 (tr) 2018-09-21
EA030646B1 (ru) 2018-09-28
JP2018150316A (ja) 2018-09-27
SG10201609940RA (en) 2016-12-29
US10689375B2 (en) 2020-06-23
MY177344A (en) 2020-09-13
PL2922850T3 (pl) 2018-12-31
SA515360469B1 (ar) 2017-07-11
EA201590987A1 (ru) 2015-12-30
JP2016500082A (ja) 2016-01-07
CA2893510C (en) 2021-01-19
CN108727307A (zh) 2018-11-02
US10087172B2 (en) 2018-10-02
HK1214593A1 (zh) 2016-07-29
AU2013347771A1 (en) 2015-06-11
EP3456719A1 (en) 2019-03-20
JP6333277B2 (ja) 2018-05-30
WO2014079011A1 (en) 2014-05-30
PH12015501150A1 (en) 2015-08-17
PE20151072A1 (es) 2015-08-26
CR20150316A (es) 2015-08-28
TW201427963A (zh) 2014-07-16
WO2014079136A1 (en) 2014-05-30
LT2922850T (lt) 2018-09-10
SI2922850T1 (sl) 2018-10-30
ECSP15026557A (es) 2016-01-29
WO2014079150A1 (en) 2014-05-30
EP2922850A4 (en) 2016-05-18
TWI629268B (zh) 2018-07-11
EP2922850A1 (en) 2015-09-30
EP2922850B1 (en) 2018-07-18
CN104936954A (zh) 2015-09-23

Similar Documents

Publication Publication Date Title
CL2015001392A1 (es) Compuestos y sus métodos de empleo
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
CL2018003282A1 (es) Métodos y composiciones para el tratamiento de cánceres resistentes a los inhibidores de la vía no erk mapk
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
CO7111274A2 (es) Moduladores dll3 y métodos de empleo
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
MX2019003984A (es) Formulaciones de enzalutamida.
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
EA201790785A1 (ru) Производные тетрагидроизохинолина
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
UY34071A (es) Micropartícula inyectable de liberación controlada
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
GEP20186871B (en) Benzamide and nicotinamide compounds and methods of using same
BR112014031785A2 (pt) composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
UY33926A (es) Método y disposición para calcinar lodos de cal
UY34753A (es) Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
BR112014012945A2 (pt) sistemas, dispositivos e métodos para acionar um modulador interferométrico analógico